509 A phase I clinical trial of RNF43 peptide-specific immune cell therapy combined with low dose cyclophosphamide for patients with advanced solid tumorsYasuhiro Hijikata, Hiroaki Ogata, Teiji Okazaki et al.|European Journal of Cancer|2015Cited by 0